Pairidex Inc. Press Releases - EIN Presswire - Press Release Distribution Service

Published on September 22, 2026 - 09:00 GMT

Haematologica Publication Highlights Earlier Leukemia Relapse Detection with FusionMRD™ developed by Pairidex

Novel blood-based MRD testing detects treatment failure weeks to months earlier than standard of care testing. ST. LOUIS, MO, UNITED STATES, September 22, 2026 /⁨EINPresswire.com⁩/ -- Pairidex Inc., a leader in personalized disease monitoring for fusion- …

Distribution channels: Healthcare & Pharmaceuticals Industry ...

Published on July 27, 2026 - 15:48 GMT

Pairidex Closes Over-Subscribed Seed Round to Support the Launch of New Highly Sensitive MRD Test for Leukemia.

The financing brings in $4.89M in new capital to accelerate the commercial launch of FusionMRD™ ST. LOUIS, MO, UNITED STATES, July 27, 2026 /⁨EINPresswire.com⁩/ -- Pairidex, a precision diagnostics company advancing personalized molecular testing for …

Distribution channels: Healthcare & Pharmaceuticals Industry ...

Published on February 23, 2026 - 11:00 GMT

Pairidex Secures Lead Investment from BioGenerator Ventures for the Launch of New Highly Sensitive MRD Test for Leukemia

Reducing Uncertainty in the Care and Treatment of Blood Cancer ST. LOUIS, MO, UNITED STATES, February 23, 2026 /⁨EINPresswire.com⁩/ -- Pairidex, an emerging leader in leukemia detection, today announced a lead investment from BioGenerator Ventures that …

Distribution channels: Healthcare & Pharmaceuticals Industry ...

Published on November 6, 2025 - 11:00 GMT

Pairidex announces new clinical test to monitor leukemia patient therapeutic response

Pairidex today announced the launch of FusionMRD™, for the monitoring of measurable residual disease (MRD) in fusion-driven hematological malignancies. ST. LOUIS, MO, UNITED STATES, November 6, 2025 /⁨EINPresswire.com⁩/ -- Pairidex, an emerging leader in …

Distribution channels: Healthcare & Pharmaceuticals Industry ...